The Great Healthcare Debate 7 DAYS · Free panel + drinks · 12 May · London RSVP free →

EU policies "have negative" R&D impact

17 November 2008

Despite the emphasis placed by the European Union on innovation and competitiveness since the 2000 Lisbon strategy, many regulations penalize research-based businesses, including in the pharmaceutical industry, according to a new report by the France-based think-tank, the Institut economique Molinari. The paper, titled Risks and regulatory obstacles for innovating companies in Europe, draws attention to the importance of investment risks that are inherent in the R&D process, noting for example, that it takes 10,000 molecules to generate one successful drug.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight